Myelomatous meningitis

Cancer

Volumn 112, Issue 7, 2008, Pages 1562-1567

  Chamberlain, Marc C ^a,d   Glantz, Michael ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Complication; Intracerebrospinal fluid chemotherapy; Involved field radiotherapy; Myelomatous meningitis; Outcome; Treatment

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIPYRETIC AGENT; CYTARABINE; DEXAMETHASONE; METHYLPHENIDATE; MODAFINIL; RADIOISOTOPE; STEROID;

ADULT; AGED; ARACHNOIDITIS; ARTICLE; BRAIN VENTRICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID FLOW; CHEMOTHERAPY INDUCED EMESIS; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG FEVER; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MALE; MENINGISM; MENINGITIS; MULTIPLE MYELOMA; MYELOMATOUS MENINGITIS; NAUSEA; NECK PAIN; NEUROLOGIC DISEASE; PLEOCYTOSIS; PRIORITY JOURNAL; SYSTEMIC DISEASE; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; MALE; MENINGITIS, ASEPTIC; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 41149164311     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23330     Document Type: Article

References (15)

1. Schluterman KO, Fassas A, Van Hemert R, Sami HI. Multiple myeloma invasion of the central nervous system. Arch Neurol. 2004;61:1423-1429.
2. Patriarca F, Zaja F, Silvestri F, et al. Meningeal and cerebral involvement in multiple myeloma patients. Ann Hematol. 2001;80:758-762.
3. Slager UE, Taylor WF, Opfell RW, Myers A. Leptomeningeal myeloma. Arch Pathol Lab Med. 1979;103:680-682.
4. Spiers ASD, Halpern R, Ross SC, Nieman RS, Harawi S, Zipoli TE. Meningeal myelomatosis. Arch Intern Med. 1980;140:256-259.
5. Leifer D, Grabowski T, Simonian N, Demirjian ZN. Leptomeningeal myelomatosis presenting with mental status changes. Cancer. 1992;70:1899-1904.
6. de la Fuente J, Prieto I, Albo C, Sopena B, Somolinos N, Martinez C. Plasma cell myeloma presenting as myelomatous meningitis. Eur J Haematol. 1994;53:244-245.
7. Cavanna L, Invernizzi R, Berte R, Vallisa D, Buscarini L. Meningeal involvement with multiple myeloma. Acta Cytol. 1996;40:571-575.
8. Peterson SL, Winger A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation: a case report and review of the literature. Am J Hematol. 1999;62:228-233.
9. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561-569.
10. Hitchens R, Bell D, Woods R, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655-1662.
11. Glantz M, Jaeckle KA, Chamberlain MC, et al. A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116.
12. Glantz M, Jaeckle K, Chamberlain MC, et al. A randomized trial comparing intrathecal sustained-release ara-C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;11:3394-3402.
13. Kaplan EL, Meier P. Nonparametric estimation form incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40:2726-2733.
15. Rubenstein JI, Fridlyand J, Abrey L, et al. Phase 1 study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25:1350-1356.